Maravai LifeSciences Holdings Inc. Class A Common Stock vs Valero Energy Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Valero Energy Corporation trades at $460.63 (market cap $131.43B). The key difference: Valero Energy Corporation is far larger — about 135.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Valero Energy Corporation pays a 1.05% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Valero Energy Corporation for 57 Days on average.
| MRVI | VLO | |
|---|---|---|
Market Cap | $972.90M | $131.43B |
Volume | 4,325,710 | 2,513,030 |
Sector | Health | Energy |
52-Week High | $9.00 | $459.78 |
52-Week Low | $2.83 | $156.39 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.08B | $134.90B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Valero Energy (VLO) trades at $459.78, up 5.45% today, near its 52-week high. The stock exhibits strong bullish momentum with recent earnings beats and positive technical signals. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a 56.76% buy rating, though the current price exceeds the $408.10 consensus target. Recent news highlights institutional inflows and refining margin strength.
Outlook is positive due to earnings momentum and favorable sector trends, but risks include potential policy impacts on diesel exports and high valuation multiples. The stock's proximity to resistance at $460 suggests near-term consolidation may occur. Long-term growth depends on sustaining refining margins and cash flow generation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →